Tranexamic acid decreases blood loss during transurethral resection of the prostate (TUR -P)

Sükrü Kumsar, Ayhan Dirim, Serdar Toksöz, Hasan S Sağlam, Oztuğ Adsan, Sükrü Kumsar, Ayhan Dirim, Serdar Toksöz, Hasan S Sağlam, Oztuğ Adsan

Abstract

Introduction: Postoperative blood loss after prostate surgery is thought to be associated with an increase in urinary fibrinolytic activity. Tranexamic acid (TXA) is both a potent inhibitor of plasminogen and urokinase activators and a low molecular weight substance that is excreted unchanged in the urinary tract and can be administered both orally and intravenously. We investigated the effect of TXA on the amount of blood loss during transurethral resection of the prostate (TURP).

Materials and methods: Forty patients with registry numbers ending in even numbers were allocated to the treatment group; those ending in odd numbers were used as controls and received no treatment. The treatment group received 10 mg/kg TXA by intravenous infusion during the first half hour of the operation, while the control group of patients received no medication. Serum hemoglobin was measured before and after surgery. The volume and hemoglobin concentration of the irrigation fluid, resected prostate weight, and duration of resection were recorded.

Results: The mean loss of hemoglobin per gram of resected prostate tissue was 1.25 g in the TXA group and 2.84 g in the control group. Total hemoglobin loss in the irrigating fluid and hemoglobin loss per 1 gram of prostate tissue was lower in the group of patients given TXA than in the control group (p = 0.018 and p <0.001).

Conclusion: Reduced bleeding during TURP as a result of TXA treatment may lead to better surgical conditions and, as a consequence, shorter operative times and lower irrigating fluid volumes.

Keywords: prostate; prostatic hyperplasia; tranexamic acid; transurethral resection of the prostate.

References

    1. Meigs JB, Mohr B, Barry MJ, et al. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clinical Epidemiology. 2011;54:935–944.
    1. Borboroglu PG, Kane CJ, Ward JF, et al. Immediate and postoperative complications of transurethral prostatectomy in the 1990s. J Urol. 1999;162:1307–1310.
    1. Erstad BL. Systemic hemostatic medications for reducing surgical blood loss. Ann Pharmacother. 2001;35:925–934.
    1. Nielsen JD, Gram J, Fabrin A, et al. Lack of correlation between blood fibrinolysis and the immediate or post-operative blood loss in transurethral resection of the prostate. Br J Urol. 1997;80:105–110.
    1. Mannucci PM. Hemostatic drugs. N Engl J Med. 1998;339:245–253.
    1. Madsen PO, Strauch AE. The effect of aminocaproic acid on bleeding following transurethral prostatectomy. J Urol. 1966;96:255–256.
    1. Sharifi R, Lee M, Ray P, et al. Safety and efficacy of intravesical aminocaproic acid for bleeding after transurethral resection of prostate. Urology. 1986;27:214–219.
    1. Miller RA, May MW, Hendry WF, et al. The prevention of secondary haemorrhage after prostatectomy: the value of antifibrinolytic therapy. Br J Urol. 1980;52:26–28.
    1. Rannikko A, Petas A, Taari K. Tranexamic acid in control of primary hemorrhage during transurethral prostatectomy. Urology. 2004;64:955–958.
    1. Ekengren JC, Hohn RG. Blood loss during transurethral resection of the prostate as measured with the Hemocue photometer. Scand J Urol Neph. 1993;27:501–507.
    1. Donohue JF, Sharma H, Abraham R, et al. Transurethral prostate resection and bleeding: a randomized, placebo controlled trial of the role of finasteride for decreasing operative blood loss. J Urol. 2002;168:2024–2026.
    1. Hagerty JA, Ginsberg JD, Harmon JD, et al. Pretreatment with finasteride decreases perioperative bleeding associated with transurethral resection of the prostate. Urology. 2000;55:684–689.
    1. Sandfeldt L, Bailey DM, Hahn RG. Blood loss during transurethral resection of the prostate after 3 months of treatment with finasteride. Urology. 2001;58:972–976.
    1. Puchner PJ, Miller MI. The effects of finasteride on hematuria associated with benign prostatic hyperplasia: a preliminary report. J Urol. 1995;154:1779–1782.
    1. Hahn RG, Ekengren JC. Patterns of irrigating fluid absorption during transurethral resection of the prostate as indicated by ethanol. J Urol. 1993;149:502–506.
    1. Berntorp E, Follrud C, Lethagen S. No increased risk of venous thrombosis in women taking tranexamic acid. Thromb Haemost. 2001;86:714–715.
    1. Ruel MA, Wang F, Bourke ME, et al. Is tranexamic acid safe in patients undergoing coronary endarterectomy? Ann Thorac Surg. 2001;71:1508–1511.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj